Compare ECF & TNYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ECF | TNYA |
|---|---|---|
| Founded | 1986 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 162.7M | 153.2M |
| IPO Year | N/A | 2021 |
| Metric | ECF | TNYA |
|---|---|---|
| Price | $11.75 | $0.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $3.20 |
| AVG Volume (30 Days) | 44.5K | ★ 2.9M |
| Earning Date | 01-01-0001 | 11-09-2026 |
| Dividend Yield | ★ 6.42% | N/A |
| EPS Growth | N/A | ★ 54.96 |
| EPS | ★ 0.46 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $26.09 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.71 | $0.52 |
| 52 Week High | $13.85 | $2.02 |
| Indicator | ECF | TNYA |
|---|---|---|
| Relative Strength Index (RSI) | 37.77 | 20.97 |
| Support Level | $11.16 | N/A |
| Resistance Level | $12.68 | $0.81 |
| Average True Range (ATR) | 0.18 | 0.04 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 11.20 | 14.29 |
Ellsworth Growth and Income Fund Ltd operate as a closed-end, diversified management investment company. Its investment objective is to provide income and the potential for capital appreciation, which objectives the Fund considers to be relatively equal over the long term due to the nature of the securities in which it invests. The company invests in convertible and equity securities. It invests in various sectors, such as healthcare, financial services, computer software and services, energy and utilities, real estate investment trusts, semiconductors, telecommunications, business services, food and beverage, consumer products, transportation, consumer services among others.
Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.